Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_assertion type Assertion NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_head.
- NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_assertion description "[Therefore, concomitant administration of HDACIs and ERK1/2 inhibitors may be a promising treatment strategy for individuals with GC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_provenance.
- NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_assertion evidence source_evidence_literature NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_provenance.
- NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_assertion SIO_000772 22781708 NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_provenance.
- NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_assertion wasDerivedFrom befree-20150227 NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_provenance.
- NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_assertion wasGeneratedBy ECO_0000203 NP645033.RAbHM0OLm2-ojY6XTpxi7CNF97DPlCNwG4MNHrfgWFQjc130_provenance.